The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
- Author(s)
- Rayson, VC; Harris, MA; Savas, P; Hun, ML; Virassamy, B; Salgado, R; Loi, S;
- Details
- Publication Year 2024-06,Volume 10,Issue #6,Page 490-506
- Journal Title
- Trends in Cancer
- Publication Type
- Review
- Abstract
- Triple-negative breast cancers (TNBCs) exhibit heightened T cell infiltration, contributing to an enhanced response to immune checkpoint blockade (ICB) compared with other subtypes. An immune-rich immune microenvironment correlates with improved prognosis in early and advanced TNBC. Combination chemotherapy and ICB is now the standard of care in early- and late-stage TNBC. Although programmed death ligand-1 (PD-L1) positivity predicts ICB response in advanced stages, its role in early-stage disease remains uncertain. Despite neoadjuvant ICB becoming common in early-stage TNBC, the necessity of adjuvant ICB after surgery remains unclear. Understanding the molecular basis of the immune response in breast cancer is vital for precise biomarkers for ICB and effective combination therapy strategies.
- Publisher
- Cell Press
- Keywords
- Humans; Female; *Triple Negative Breast Neoplasms/immunology/drug therapy/therapy/pathology; *Biomarkers, Tumor/immunology; *Immune Checkpoint Inhibitors/therapeutic use/pharmacology; *Tumor Microenvironment/immunology/drug effects; *Neoadjuvant Therapy/methods; B7-H1 Antigen/antagonists & inhibitors/immunology/metabolism; Antineoplastic Combined Chemotherapy Protocols/therapeutic use/pharmacology; Prognosis; Chemotherapy, Adjuvant/methods; immune checkpoint blockade; immune response; triple-negative breast cancer (TNBC); tumor infiltrating lymphocytes
- Department(s)
- Medical Oncology; Laboratory Research
- Publisher's Version
- https://doi.org/10.1016/j.trecan.2024.02.008
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-27 04:47:42
Last Modified: 2024-08-27 04:47:56